Author Topic: (Abst.) Age-related MS: Disability ranked by age  (Read 62 times)

0 Members and 1 Guest are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 9822
  • MS diagnosed 1980
  • Location: Pacific Northwest
(Abst.) Age-related MS: Disability ranked by age
« on: November 21, 2017, 04:06:39 pm »
Usually when the extent of a person's disability is being discussed, it is correlated with the number of years since MS onset.  This article suggests that a better, more reliable method might be to correlate it with the person's age--since the date of MS onset is often hard to determine.

From Multiple Sclerosis Journal, December 2017:

Quote
Age Related Multiple Sclerosis Severity Score: Disability ranked by age

Ali Manouchehrinia, Helga Westerlind, Elaine Kingwell, Feng Zhu, Robert Carruthers, Ryan Ramanujam, Maria Ban, Anna Glaser, Stephen Sawcer, Helen Tremlett, Jan Hillert

 
Background:

The Multiple Sclerosis Severity Score (MSSS) is obtained by normalising the Expanded Disability Status Scale (EDSS) score for disease duration and has been a valuable tool in cross-sectional studies.

Objective:

To assess whether use of age rather than the inherently ambiguous disease duration was a feasible approach.

Method:

We pooled disability data from three population-based cohorts and developed an Age Related Multiple Sclerosis Severity (ARMSS) score by ranking EDSS scores based on the patient’s age at the time of assessment. We established the power to detect a difference between groups afforded by the ARMSS score and assessed its relative consistency over time.

Results:

The study population included 26058 patients from Sweden (n = 11846), Canada (n = 6179) and the United Kingdom (n = 8033). There was a moderate correlation between EDSS and disease duration (r = 0.46, 95% confidence interval (CI): 0.45–0.47) and between EDSS and age (r = 0.44, 95% CI: 0.43–0.45). The ARMSS scores showed comparable power to detect disability differences between groups to the updated and original MSSS.

Conclusion:

Since age is typically unbiased and readily obtained, and the ARMSS and MSSS were comparable, the ARMSS may provide a more versatile tool and could minimise study biases and loss of statistical power caused by inaccurate or missing onset dates.
MS Speaks--online for 17 years

SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010. Glatopa (glatiramer acetate 40mg 3 times/week) since 12/16/20.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
100 Views
Last post February 05, 2017, 03:57:52 pm
by agate
0 Replies
35 Views
Last post May 21, 2020, 08:54:50 pm
by agate
0 Replies
34 Views
Last post November 02, 2020, 09:33:53 pm
by agate
0 Replies
35 Views
Last post October 25, 2022, 09:20:47 pm
by agate
0 Replies
21 Views
Last post November 25, 2022, 04:08:18 pm
by agate